Monte Rosa Therapeutics (NASDAQ:GLUE) and Sana Biotechnology (NASDAQ:SANA) Head to Head Review

Sana Biotechnology (NASDAQ:SANA) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Sana Biotechnology and Monte Rosa Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1	1	7	1	2.80
Monte Rosa Therapeutics	1	1	6	1	2.78

Sana Biotechnology currently has a consensus price target of $9.33, suggesting a potential upside of 124.36%. Monte Rosa Therapeutics has a consensus price target of $28.50, suggesting a potential upside of 98.19%. Given Sana Biotechnology’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Sana Biotechnology is more favorable than Monte Rosa Therapeutics.

Profitability

This table compares Sana Biotechnology and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Valuation and Earnings

This table compares Sana Biotechnology and Monte Rosa Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17 million	($0.76)	-5.47
Monte Rosa Therapeutics	$123.67 million	9.92	-$38.63 million	($1.76)	-8.17

Monte Rosa Therapeutics has higher revenue and earnings than Sana Biotechnology. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Sana Biotechnology has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Summary

Sana Biotechnology beats Monte Rosa Therapeutics on 9 of the 13 factors compared between the two stocks.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.